Editas Medicine

$34.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$6.31 (-15.40%) Today
-$0.13 (-0.37%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell EDIT and other stocks, options, and ETFs commission-free!

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).

CEO
James C. Mullen
Employees
235
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
2.22B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.40M
High Today
$39.22
Low Today
$33.58
Open Price
$38.15
Volume
6.79M
52 Week High
$99.95
52 Week Low
$21.41

EDIT News

BenzingaApr 13

CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends

Los Angeles, USA, April 12, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings a

EDIT Earnings

-$1.00
-$0.63
-$0.25
$0.12
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 6, Pre-Market

You May Also Like

JAPAY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure